Furthermore, we showed that temozolomide treatment suppressed SOX10 in glioblastoma model systems, resulting in the enrichment of a slow-cycling SOX9/p27 double-positive cell population, suggesting a role for SOX10-dependent cell-state transitions in therapy-associated tumor progression. This evidence concerns the gene SOX10 and glioblastoma.